Publications and Digital Products

This Advisory highlights the importance of methadone as a tool for treating incarcerated with people with opioid use disorder (OUD). The Advisory describes different institutional arrangements for providing methadone in correctional settings.

The Guidelines address the implementation of medications for opioid use disorder (MOUD) in state prisons and practical information about medications, service delivery models, regulatory requirements, staff training, and cultural issues that may affect the uptake and integration of MOUD.

The primary objective of this report and issue brief is to analyze and understand trends, patterns, and disparities in mental health and substance use disorder screening, collaborative care, and OUD/AUD medication treatment service utilization among older adults.

Monitoring the distribution and impact of opioid overdose reversal medications such as naloxone is essential to optimizing overdose prevention strategies and improving public health outcomes. This Statistical Data Profile, the first to use performance data from two SAMHSA grant programs, examines the distribution of FDA-approved opioid overdose reversal medications, including naloxone/Narcan. The Data Profile also presents the training of first responders, community organization staff and other individuals to administer the reversal medications and provide other support services.

This report presents data from DAWN using national estimates and trends of opioid-involved emergency department (ED) visits in the United States, including those involving prescription opioids, fentanyl, heroin, and opioids not otherwise specified.

This Spotlight highlights a notable finding from the evaluation of SAMHSA’s Projects for Assistance in Transition from Homelessness (PATH) program published in 2024. The PATH program is intended to reduce homelessness among persons experiencing severe mental illness or co-occurring mental illness and substance use disorders. PATH collects data on the reported residence of clients the night prior to enrolling in services. An examination of these data for FY 2019 to 2021 revealed an approximately ten-point percentage increase of PATH clients reporting being in an unsheltered situation the night prior to enrollment.

Find data on the nonuse of substances among adolescents aged 12 to 17 from the 2023 National Survey on Drug Use and Health (NSDUH). Estimates include illicit drugs, alcohol, tobacco products, and nicotine vaping.

The STOP Act requires an annual report on each State's performance in enacting, enforcing, and creating laws, regulations, and programs to prevent or reduce underage drinking. 

This State Report primarily includes data from calendar year 2022 and 2023. Regional and state profile data were drawn from the most recently available federal survey data as of 2022. State legal data reflect the status of the law as of January 1, 2023. State survey data, collected in 2023, were drawn from the most recent 12-month period in which the states maintained the data.